Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.
نویسندگان
چکیده
Deregulated protein and Ca2+ homeostasis underlie synaptic dysfunction and neurodegeneration in Huntington disease (HD); however, the factors that disrupt homeostasis are not fully understood. Here, we determined that expression of downstream regulatory element antagonist modulator (DREAM), a multifunctional Ca2+-binding protein, is reduced in murine in vivo and in vitro HD models and in HD patients. DREAM downregulation was observed early after birth and was associated with endogenous neuroprotection. In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of motor dysfunction, reduced striatal atrophy, and prolonged life span. DREAM-related neuroprotection was linked to an interaction between DREAM and the unfolded protein response (UPR) sensor activating transcription factor 6 (ATF6). Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons. Together, our results identify a role for DREAM silencing in the activation of ATF6 signaling, which promotes early neuroprotection in HD.
منابع مشابه
Expression and Clinical Significance of Activating Transcription Factor 3 in Human Breast Cancer
Objective(s): Breast cancer is the most common type of cancer among women worldwide. This study investigated the expression and clinical significance of activating transcription factor 3 (ATF3) in human breast cancer and its relationship with the clinical outcome of breast cancer. Materials and Methods : ATF3 expressions were detected in 114 primary breast cancer tissues and ...
متن کاملIdentification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans
BACKGROUND The prolonged time course of Huntington's disease (HD) neurodegeneration increases both the time and cost of testing potential therapeutic compounds in mammalian models. An alternative is to initially assess the efficacy of compounds in invertebrate models, reducing time of testing from months to days. METHODOLOGY/PRINCIPAL FINDINGS We screened candidate therapeutic compounds that ...
متن کاملActivating the PARP-1 Sensor Component of the Groucho/ TLE1 Corepressor Complex Mediates a CaMKinase IIδ-Dependent Neurogenic Gene Activation Pathway
Switching specific patterns of gene repression and activation in response to precise temporal/spatial signals is critical for normal development. Here we report a pathway in which induction of CaMKIIdelta triggers an unexpected switch in the function of the HES1 transcription factor from a TLE-dependent repressor to an activator required for neuronal differentiation. These events are based on a...
متن کاملP 129: The Role of Overexpression Transcription Factor BRN 4 in Multiple Sclerosis
Adult neurogenesis is a process of producing nerve cells from their progenitor that occurs in some areas in the brain such as the hypothalamus. Low activity in this area plays a role in neural degeneration and diseases such as multiple sclerosis, epilepsy and depression. MS is a neurodegenerative disease with a permanent disability that the main reason for it is axonal degeneration and neuronal...
متن کاملNeuroprotection and restoration of the nigrostriatal dopaminergic system in 6-OHDA lesioned rat model of Parkinson's disease: Role of GDNF and TGF expressing Zuckerkandl's organ
Zuckerkandl’s organ (ZK) is an extra adrenal para-ganglion and has the ability to express glial cell line derived neurotrophic factor (GDNF) and transforming growth factor (TGF). It is also a source of dopamine and norepinephrine. In the present study, the neuroprotective and restorative potential of ZK was studied by transplanting it into the striatum of adult rats either before or after the i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of clinical investigation
دوره 126 2 شماره
صفحات -
تاریخ انتشار 2016